To evaluate the clinical potential of our findings, we established a gastric PM model using the MFC mouse gastric cancer cell line and treated the mice with intraperitoneal injections of pralsetinib, a clinically used RET inhibitor, every three days. Here, RET is linked to gastric cancer.